Rapid Micro Biosystems Appoints Michael Beaulieu as Vice President, Investor Relations and Corporate Communications
LOWELL, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the appointment of Michael Beaulieu as Vice President, Investor Relations and Corporate Communications.
“We are excited to welcome Mike to the Rapid Micro team,” said Sean Wirtjes, Chief Financial Officer. “He brings a deep understanding of the healthcare investment community that will be invaluable as we continue to expand our outreach and engagement and increase awareness of our automated microbial QC solution. We are confident his established relationships with various stakeholders, including institutional investors, will help us with these efforts and our goal of creating long-term value for our shareholders.”
Beaulieu brings over two decades of experience in investor relations, communications, and equity research. Most recently, he served as Head of Investor Relations at Integra LifeSciences Holding Corporation (“Integra”). While at Integra, he was named to the Institutional Investor All-America Team, Best IR Professionals for Life Sciences & Diagnostic Tools & Medical Supplies and Devices. Previously, he was a senior equity research analyst at AIG SunAmerica, PNC Advisors, and Merrill Lynch Investment Managers. Beaulieu has a BS from the University of Vermont, an MBA from the Fordham Gabelli School of Business, and is a Chartered Financial Analyst.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications firstname.lastname@example.org Media Contact: email@example.com